Chest Medicine | Page 38 of 170 | Links Medicus Content Curation & Alerts in Medicine

Guideline Summary: Management of the top 10 most common immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.

30 Jan, 2022 | 14:11h | UTC

Management of the Top 10 Most Common Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy – JCO Oncology Practice

Original Article: ASCO Guideline Update: Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy.

Clinical practice guideline on immune checkpoint inhibitor-related adverse events.

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities (several resources on the subject)

Perspective | Where do we stand with Omicron? The data, the math, the patterns, and the exit.

28 Jan, 2022 | 08:39h | UTC

Where do we stand with Omicron? – by Dr. Eric Topol

Commentary on Twitter

Where do we stand with Omicron?
I've summarized the new data, math, patterns, and potential exit ramphttps://t.co/SyCmCzkBQX @SubstackInc

— Eric Topol (@EricTopol) January 22, 2022

Clinical characteristics and outcomes of patients with COVID-19–Associated Acute Respiratory Distress Syndrome who underwent lung transplant.

28 Jan, 2022 | 08:41h | UTC

Clinical Characteristics and Outcomes of Patients With COVID-19–Associated Acute Respiratory Distress Syndrome Who Underwent Lung Transplant – JAMA

RCT: Hyperimmune immunoglobulin did not improve outcomes in hospitalized patients with COVID-19.

28 Jan, 2022 | 08:42h | UTC

Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial – The Lancet

Commentaries:

High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19 – The Lancet

Hyperimmune intravenous immunoglobulin does not improve outcomes for adults hospitalized with COVID-19 – NIH News Releases

After Omicron, some scientists foresee ‘a period of quiet’.

28 Jan, 2022 | 08:36h | UTC

After Omicron, some scientists foresee ‘a period of quiet’ – Science

ELSO Guidelines for anticoagulation in adult and pediatric patients using extracorporeal membrane oxygenation (ECMO).

28 Jan, 2022 | 08:26h | UTC

2021 ELSO Adult and Pediatric Anticoagulation Guidelines – ASAIO Journal

Commentary on Twitter

The updated @ELSOOrg adult & pediatric anticoagulation guidelines just out, open access, on @asaiojournal
🩸anticoagulants
🩸therapeutic monitoring of anticoagulants
🩸management of bleeding & thrombotic complications#FOAMcc #FOAMecmo #PedsICU
🖇 https://t.co/sC8iQK6YL0 pic.twitter.com/hkbVoNBDkR

— ELSO (@ELSOOrg) January 21, 2022

Lab study shows new antiviral pills maintain efficacy against Omicron, but antibody drugs are substantially less effective.

27 Jan, 2022 | 10:03h | UTC

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant – New England Journal of Medicine

Commentary: Current anti-COVID pills work well against omicron, but antibody drugs are less effective, study finds – University of Wisconsin-Madison

Commentary on Twitter

Investigators assessed the in vitro activities of seven monoclonal antibodies & three antiviral drugs against #COVID19 variants. All antibodies showed no or weak neutralizing activity against omicron; two drugs effective at omicron neutralization. https://t.co/rOZzmtsDZS pic.twitter.com/shfKDW6r5q

— NEJM (@NEJM) January 26, 2022

Cases of lung transplantation for Covid-19–related respiratory failure in the US were associated with a three-month survival of 95.6%.

27 Jan, 2022 | 10:00h | UTC

Lung Transplantation for Covid-19–Related Respiratory Failure in the United States – New England Journal of Medicine

Commentaries:

New data on COVID-19 lung transplants – Cedars-Sinai Medical Center

~7 Percent of Lung Transplants Due to COVID-19 Respiratory Failure – HealthDay

Comprehensive review of chest tube management.

27 Jan, 2022 | 09:40h | UTC

Comprehensive Review of Chest Tube Management – JAMA Surgery (free for a limited period)

Cohort study: Among patients who survived ICU treatment for COVID-19, 75% still reported physical, mental, or cognitive symptoms after 1 year.

26 Jan, 2022 | 02:28h | UTC

Clinical Outcomes Among Patients With 1-Year Survival Following Intensive Care Unit Treatment for COVID-19 – JAMA

Commentaries:

75% of COVID ICU survivors have physical symptoms 1 year on – CIDRAP

Majority of COVID-19 survivors experience health problems one-year post ICU admission – News Medical

RCT: Acetazolamide prevents adverse altitude effects in COPD and healthy adults.

26 Jan, 2022 | 01:53h | UTC

Acetazolamide to Prevent Adverse Altitude Effects in COPD and Healthy Adults – NEJM Evidence

RCT: Electronic directly observed therapy is noninferior to in-person observed therapy for ensuring adherence to tuberculosis treatment.

26 Jan, 2022 | 01:58h | UTC

In-Person vs Electronic Directly Observed Therapy for Tuberculosis Treatment Adherence: A Randomized Noninferiority Trial – JAMA Network Open

Commentary on Twitter

In this 2-year study, data showed that electronic directly observed therapy (eDOT) was as effective as traditional in-person DOT for ensuring high adherence to treatment of tuberculosis disease. @CDC_TB @nycHealthy @ColumbiaMed https://t.co/yTrU1JRuwn pic.twitter.com/QXthE4d266

— JAMA Network Open (@JAMANetworkOpen) January 20, 2022

A registry study with 1,581 cases of Stenotrophomonas maltophilia blood and/or lower respiratory infections suggest Levofloxacin is a reasonable alternative to standard therapy with Trimethoprim-sulfamethoxazole.

26 Jan, 2022 | 01:40h | UTC

Trimethoprim-Sulfamethoxazole versus Levofloxacin for Stenotrophomonas maltophilia Infections: A Retrospective Comparative Effectiveness Study of Electronic Health Records from 154 U.S. Hospitals – Open Forum Infectious Diseases

Commentary on Twitter

A new study in OFID suggests that mortality outcomes are similar comparing levofloxacin and TMP/SMX treatment of S. maltophilia lower respiratory tract and bloodstream infections.

📄:https://t.co/80QDy3DTU9 #IDSAJournals @PaulSaxMD @DrJLi @Keith_S_Kaye @SameerKadri12 pic.twitter.com/TNxQpfT97n

— IDSA (@IDSAInfo) January 23, 2022

Systematic Review: Oral antihistamine‐decongestant‐analgesic combinations for the common cold.

26 Jan, 2022 | 01:31h | UTC

Oral antihistamine‐decongestant‐analgesic combinations for the common cold – Cochrane Library

Commentary: Oral antihistamine-decongestant-analgesic combinations for the common cold – Cochrane Library

RCT: CPAP improved outcomes in patients with acute hypoxemic respiratory failure due to COVID-19, but high-flow nasal oxygen was not better than conventional oxygen therapy.

25 Jan, 2022 | 09:50h | UTC

Effect of Noninvasive Respiratory Strategies on Intubation or Mortality Among Patients With Acute Hypoxemic Respiratory Failure and COVID-19: The RECOVERY-RS Randomized Clinical Trial – JAMA

Editorial: Defining Optimal Respiratory Support for Patients With COVID-19 – JAMA

Commentary on Twitter

RCT of patients with acute hypoxemic respiratory failure due to #COVID19 found an initial strategy of CPAP, compared with conventional oxygen therapy, significantly reduced the composite outcome of tracheal intubation or mortality within 30 days. https://t.co/fznFigiFmu pic.twitter.com/b7mHssbfkp

— JAMA (@JAMA_current) January 24, 2022

ACP living, rapid review: risk for reinfection after SARS-CoV-2.

25 Jan, 2022 | 09:47h | UTC

Risk for Reinfection After SARS-CoV-2: A Living, Rapid Review for American College of Physicians Practice Points on the Role of the Antibody Response in Conferring Immunity Following SARS-CoV-2 Infection – Annals of Internal Medicine

Commentary on Twitter

Risk for Reinfection After #SARSCoV2: previous infection reduced risk for reinfection by 87% (95% CI, 84% to 90%). Protection remained above 80% for at least 7 months, but no study followed patients after the emergence of the Delta or #Omicron variant. https://t.co/eruEf1w8Vo

— Prof. Nick Talley (@Prof_NickTalley) January 25, 2022

WHO drops opposition to boosters – recommends third Pfizer jab for adults & two vaccines for children ages 5 & up.

25 Jan, 2022 | 09:45h | UTC

WHO Drops Opposition to Boosters – Recommends Third Pfizer Jab for Adults & Two Vaccines for Children Ages 5 & Up – Health Policy Watch

WHO updated roadmap for prioritizing uses of COVID-19 vaccines.

WHO advisers weigh in on COVID-19 boosters, Pfizer vaccine in younger kids.

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa.

25 Jan, 2022 | 09:41h | UTC

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study – The Lancet

Commentary: Omicron severity: milder but not mild – The Lancet

Commentary on Twitter

Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in S. Africa, Lancet. Individuals with Omicron vs previous infections 80% lower odds of being admitted to hospital, 70% lower odds of severe disease than Deltahttps://t.co/528NWfKrDN

— Monica Gandhi MD, MPH (@MonicaGandhi9) January 23, 2022

[Preprint] Cohort study: Reduced risk of hospitalization associated with infection with SARS-CoV-2 Omicron relative to Delta.

25 Jan, 2022 | 09:40h | UTC

Reduced Risk of Hospitalisation Associated With Infection With SARS-CoV-2 Omicron Relative to Delta: A Danish Cohort Study – SSRN / Preprints with The Lancet

Commentaries:

Danish report: lower risk of hospitalisation with Omicron – Copenhagen Post

Omicron has a 36% lower risk for hospitalization compared to Delta: Denmark study – Outbreak News Today

Commentary on Twitter

New Danish population-based cohort study confirms lower (36%, 95%CI 44%-25%) risk of hospitalization with Omicron compared with Delta.
The risk also seems to be reduced irrespective of vaccination status.

Pre-print can be found here: https://t.co/LfRrw1H3CY pic.twitter.com/Ql3zPyZyRE

— Anders Husby (@a_husby) January 20, 2022

[Preprint] Omicron SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta.

25 Jan, 2022 | 09:37h | UTC

Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with Delta (B.1.617.2) – medRxiv

Commentary on Twitter

In Portugal, Omicron hospitalizations were 75% reduced compared with Delta, risk adjusted. Vaccination reduced hospitalizations 84%, w/a booster 93%https://t.co/MvkfuF3mzx pic.twitter.com/zyk2INWNis

— Eric Topol (@EricTopol) January 23, 2022

European CDC on Omicron: “among Omicron cases reported to TESSy, 1.14% were hospitalised, 0.16% required ICU admission/respiratory support, and 0.06% died”.

24 Jan, 2022 | 08:54h | UTC

Weekly epidemiological update: Omicron variant of concern (VOC) – week 2 (data as of 20 January 2022) EU/EEA – European Centre for Disease Prevention and Control (ECDC)

Case-control study: 3 doses of mRNA vaccines were associated with reduced infections with SARS-CoV-2 Omicron and Delta variants compared to no vaccination or 2 doses.

24 Jan, 2022 | 08:56h | UTC

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants – JAMA

Editorial: Booster Vaccination to Prevent COVID-19 in the Era of Omicron: An Effective Part of a Layered Public Health Approach – JAMA

Commentaries: New data show booster doses protect against Omicron – CIDRAP

Boosters provide the best protection against Omicron variant, CDC studies show, raising new questions about what it means to be fully vaccinated – CNN

Related CDC Studies:

COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence — 25 U.S. Jurisdictions, April 4–December 25, 2021 – CDC Morbidity and Mortality Weekly Report

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 – CDC Morbidity and Mortality Weekly Report

Commentary on Twitter

Study suggests receipt of 3 doses of mRNA #COVID19 vaccine, vs 2 doses or being unvaccinated, was associated with protection against both the Omicron and Delta variants; higher odds ratios for Omicron suggest less protection for Omicron than for Delta. https://t.co/kOZh0fq5TL

— JAMA (@JAMA_current) January 21, 2022